MRC Technology provides drug discovery services, as well as advice for commercialisation and intellectual property management, for academia and industry.
Since it was founded in 2000, MRC Technology helped 18 startups and 12 drugs develop from research to the market – including Merck‘s cancer drug Keytruda and Takeda‘s Entyvio for Rheumatoid arthritis. It also generated over €800M (£630M) in royalties.
This research charity has now completed its move to Stevenage Bioscience Catalyst (SBC) campus, where it will have 2140 square meters of lab space and offices.
The move was announced back in 2013, and MRC Technology is to become the cornerstone tenant in SBC’s Accelerator building. Stevenage was apparently the right place to attract collaborations with universities, Biotechs and Pharma.
It is also becoming an increasingly important innovation hub in the UK Biotech scene –